Analysts Offer Predictions for HBIO Q3 Earnings

Harvard Bioscience, Inc. (NASDAQ:HBIO) – Equities researchers at Sidoti issued their Q3 2026 EPS estimates for shares of Harvard Bioscience in a research report issued to clients and investors on Saturday, October 31st. Sidoti analyst J. Sidoti anticipates that the medical instruments supplier will post earnings of ($0.65) per share for the quarter. Sidoti also issued estimates for Harvard Bioscience’s Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($2.44) EPS, Q1 2027 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.34) EPS, Q3 2027 earnings at ($0.36) EPS, Q4 2027 earnings at ($0.09) EPS, FY2027 earnings at ($1.15) EPS, Q1 2028 earnings at $0.06 EPS, Q2 2028 earnings at $0.06 EPS, Q3 2028 earnings at $0.05 EPS and FY2028 earnings at $0.43 EPS.

Several other analysts have also recently issued reports on the company. Weiss Ratings cut Harvard Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. Benchmark boosted their price target on Harvard Bioscience from $6.00 to $7.50 and gave the stock a “speculative buy” rating in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Harvard Bioscience has a consensus rating of “Hold” and an average target price of $6.75.

Harvard Bioscience Stock Up 0.8%

Shares of HBIO stock opened at $8.67 on Wednesday. Harvard Bioscience has a 52-week low of $4.00 and a 52-week high of $9.10. The company has a debt-to-equity ratio of 4.94, a current ratio of 1.87 and a quick ratio of 0.98. The company’s 50 day moving average is $8.17 and its 200 day moving average is $6.46.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings results on Tuesday, August 11th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.07. Harvard Bioscience had a negative net margin of 11.86% and a negative return on equity of 33.13%. The firm had revenue of $22.73 million during the quarter, compared to analysts’ expectations of $21.45 million.

Institutional Trading of Harvard Bioscience

An institutional investor recently bought a new position in Harvard Bioscience stock. Meros Investment Management LP acquired a new position in Harvard Bioscience, Inc. (NASDAQ:HBIO) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 182,992 shares of the medical instruments supplier’s stock, valued at approximately $1,125,401. Meros Investment Management LP owned approximately 4.02% of Harvard Bioscience at the end of the most recent reporting period. Institutional investors and hedge funds own 80.87% of the company’s stock.

Key Headlines Impacting Harvard Bioscience

Here are the key news stories impacting Harvard Bioscience this week:

• Positive Sentiment: Sidoti forecasts Harvard Bioscience will earn $0.43 per share in fiscal 2028, with quarterly profits of $0.05–$0.06 beginning in Q1 2028. That projected turnaround could support investor optimism, though it remains a forecast. MarketBeat coverage
• Neutral Sentiment: CEO John Duke and CFO Mark Frost will participate in Canaccord Genuity’s MedTech, Diagnostics, and Digital Health and Services Forum on November 11. The announcement provides an opportunity for investor engagement but includes no new financial or operating details. Forum announcement
• Negative Sentiment: Sidoti expects continued losses in the nearer term, forecasting a $2.44-per-share loss for 2026 and a $1.15-per-share loss for 2027. Those estimates may temper the positive longer-term outlook. MarketBeat coverage

About Harvard Bioscience

Harvard Bioscience, Inc (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies.

The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.